Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis After a Change in Targeted Therapy

BACKGROUND: Targeted disease-modifying antirheumatic drug (DMARD) options for rheumatoid arthritis (RA) include tumor necrosis factor (TNF) inhibitors (adalimumab, certolizumab, etanercept, golimumab, infliximab) or alternative mechanisms of action (MOAs), such as a T-cell co-stimulation modulator (...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Am Health Drug Benefits
Main Authors: Bonafede, Machaon M. K., McMorrow, Donna, Proudfoot, Clare, Shinde, Shraddha, Kuznik, Andreas, Chen, Chieh-I
Format: Artigo
Sprog:Inglês
Udgivet: Engage Healthcare Communications, LLC 2018
Fag:
Business
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6207310/
https://ncbi.nlm.nih.gov/pubmed/30464787
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker